Life Insurance for Type 1 Diabetes

Life insurance for type 1 diabetes is available — and in many cases, individuals with well-managed type 1 diabetes qualify for meaningful coverage at competitive premiums rather than at prohibitive table ratings or outright declines. The diagnosis is not the obstacle most applicants fear. What insurers actually evaluate is whether the condition is controlled, whether complications have developed, and whether the applicant’s overall metabolic and cardiovascular profile reflects the long-term stability that translates into manageable actuarial risk. Type 1 diabetes is an autoimmune condition in which the immune system destroys the insulin-producing beta cells of the pancreas, requiring lifelong exogenous insulin management. Because the condition is permanent and carries well-documented long-term complication risks, insurance underwriters evaluate it carefully and specifically — not with a blanket exclusion, but with a detailed review of the clinical variables that actually predict long-term mortality risk for the individual applicant. An individual with type 1 diabetes whose A1C has been consistently controlled, whose specialist follow-up is current, and who has no evidence of microvascular or macrovascular complications is in a genuinely different underwriting position from an individual with the same diagnosis but poorly controlled glucose and documented end-organ damage — and the life insurance market treats those two profiles very differently.

At Diversified Insurance Brokers, Jason Stolz, CLTC, CRPC, DIA, CAA has over two decades of experience presenting type 1 diabetes cases to carriers with favorable underwriting guidelines for this condition — matching the specific clinical profile to the carrier whose underwriting philosophy produces the best outcome. The most consequential decision in life insurance for type 1 diabetes is not which product to apply for but which carrier receives the application and how that application is prepared and presented. Our resource on life insurance with pre-existing conditions covers the broader framework for underwriting complex health histories, and our resource on what will disqualify me from life insurance covers the specific clinical factors that create the most significant underwriting challenges across all conditions.

How Type 1 Diabetes Underwriting Variables Affect Life Insurance Outcomes

Underwriting for life insurance for type 1 diabetes is not a single-variable process. It is a multi-dimensional assessment that weighs each clinical factor against the overall risk picture — giving more weight to the factors that predict long-term mortality risk and less to those that are present but well-managed. The table below maps the key underwriting variables to their impact on the likely coverage outcome, from the most favorable profile elements to the most challenging.

The table reveals the most important principle in life insurance for type 1 diabetes underwriting: outcomes are driven by the overall clinical profile, not by any single variable in isolation. An applicant with a moderately elevated A1C but no complications, excellent cardiovascular health, consistent specialist oversight, and no tobacco use presents a meaningfully more favorable risk profile than the A1C number alone would suggest — and a carrier with sophisticated type 1 diabetes underwriting guidelines will evaluate that full profile rather than applying a simple threshold rule. The objective for every type 1 diabetes applicant is to document and present the most favorable elements of their clinical picture comprehensively and accurately, targeted to a carrier whose underwriting approach values controlled diabetic profiles. Our resource on life insurance for high A1C diabetics covers the specific underwriting considerations when A1C control is the primary challenge in an otherwise stable profile.

A1C and Metabolic Control — The Central Underwriting Variable

Hemoglobin A1C is the quantitative cornerstone of life insurance for type 1 diabetes underwriting because it provides a retrospective measure of average blood glucose exposure over approximately three months — a window that is simultaneously recent enough to reflect current management and long enough to capture meaningful patterns rather than single-day readings. Unlike a fasting blood glucose reading, which reflects only the moment of the test, A1C integrates the full glycemic exposure across the preceding 90 days, making it the most reliable single predictor of long-term diabetic complication risk from an actuarial perspective.

Carriers that actively underwrite type 1 diabetes cases typically establish internal A1C thresholds that trigger different underwriting classifications — with consistent readings below approximately 7.0-7.5% producing the most favorable outcomes, readings in the 7.5-8.5% range producing standard or modestly rated outcomes at favorable carriers, and readings consistently above 8.5-9.0% creating meaningful underwriting challenges. These thresholds are not uniform across all carriers — which is precisely why carrier selection matters so much. A carrier whose guidelines accommodate A1C values that another carrier treats as table-ratable can produce outcomes that feel dramatically different for the same applicant presenting the same clinical history.

The trend of A1C values over time is often as important to underwriters as the current reading. An applicant whose A1C was 8.5% two years ago and has declined to 7.2% over the past year — demonstrating improving control through a treatment change, technology adoption, or lifestyle modification — presents a more favorable narrative than an applicant whose A1C has been stable at 7.4% for years. Trending documentation matters because it shows the direction of management trajectory, which predicts future complication risk at least as well as the current reading. Providing serial A1C results covering at least two to three years gives underwriters the trajectory context that a single current reading cannot supply.

Complications — The Most Significant Underwriting Dividing Line

The presence or absence of diabetic complications is the single most consequential dividing line in life insurance for type 1 diabetes underwriting. An applicant with type 1 diabetes and no documented complications is in a categorically different underwriting position from an applicant with established microvascular or macrovascular disease — regardless of the similarity in diagnosis name. Complications represent the transition from a managed chronic condition to a condition with documented end-organ impact, and that transition changes the actuarial calculation fundamentally.

Diabetic nephropathy — kidney involvement — is tracked through urine albumin measurements and estimated glomerular filtration rate (eGFR). Early-stage nephropathy (microalbuminuria) may be treated as a ratable factor at favorable carriers while more advanced nephropathy (overt proteinuria or reduced eGFR) creates more significant underwriting challenges. Our resource on life insurance for kidney disease covers the underwriting landscape when renal function is the primary concern in addition to the diabetes history, and understanding how these two conditions interact in underwriting is important for applicants who have documented kidney involvement.

Diabetic retinopathy — eye involvement — is assessed through ophthalmology records. Background retinopathy (non-proliferative) that has been stable and does not affect visual acuity is viewed more favorably than proliferative retinopathy or any history of retinal procedures. Regular ophthalmology examinations that confirm stability or improvement are among the most valuable documentation components for an applicant with any prior retinopathy history. Peripheral neuropathy — nerve involvement — is evaluated through clinical documentation of symptoms and functional status; mild, stable neuropathy in an otherwise well-controlled profile is treated very differently from significant neuropathy with functional impairment. Our resource on life insurance for diabetics with complications covers the underwriting approach in detail when one or more complication categories are documented.

Cardiovascular Health — The Parallel Risk Dimension

Type 1 diabetes significantly elevates long-term cardiovascular risk — increasing the probability of coronary artery disease, hypertension, dyslipidemia, and cardiac events at earlier ages than the general population. This is why life insurance for type 1 diabetes underwriting does not evaluate only the diabetes metrics; it evaluates the cardiovascular profile in parallel, and a compromised cardiovascular picture compounds the diabetic risk assessment in ways that create meaningful underwriting challenges even when glucose control is otherwise good.

Blood pressure management is evaluated both independently and in the context of diabetic risk. Individuals with type 1 diabetes and well-controlled blood pressure — on or off medication — present a more favorable cardiovascular picture than those with uncontrolled or inadequately treated hypertension. Lipid profile — LDL, HDL, triglycerides — is similarly evaluated; optimized lipid management through medication, diet, and exercise contributes positively to the overall risk narrative. Our resource on life insurance for high blood pressure covers the underwriting framework for hypertension independently, which provides useful context for understanding how blood pressure interacts with the diabetes underwriting evaluation.

Any history of cardiovascular events — heart attack, stent placement, bypass surgery, significant cardiac arrhythmia — changes the underwriting picture substantially regardless of how well the diabetes is controlled. Cardiovascular history is evaluated on its own underwriting basis and then compounded with the diabetic risk, producing an overall assessment that reflects both risk dimensions simultaneously. Our resource on life insurance after a heart attack covers the cardiac underwriting framework, which applies to type 1 diabetes applicants with cardiac history as a second major underwriting variable running alongside the diabetes evaluation.

DKA and Hypoglycemia History — Stability Indicators

Diabetic ketoacidosis and severe hypoglycemia are evaluated in life insurance for type 1 diabetes underwriting as indicators of management stability — or lack thereof. Both events represent metabolic emergencies that suggest either inadequate glucose control, treatment adherence problems, illness-related management challenges, or management system failures. The timing, frequency, and context of these events determine how significantly they affect the underwriting outcome.

A single DKA episode that occurred years ago — particularly one with an identifiable precipitating cause such as illness or insulin access disruption — followed by a sustained period of documented stable control carries far less underwriting weight than recurrent DKA events or a recent episode. The carrier’s assessment of DKA history is fundamentally about whether the event pattern suggests a systemic management problem or an isolated circumstance. Providing documentation that explains the context of any DKA event and demonstrates the management stability that followed is one of the most important application preparation steps for applicants with DKA history.

Severe hypoglycemia — episodes requiring external assistance, glucagon administration, or emergency response — creates concern about glucose variability and the potential for hypoglycemia unawareness, a condition in which the normal warning symptoms of low blood sugar are blunted or absent. Hypoglycemia unawareness increases the risk of severe events because the individual cannot self-detect and self-treat before the episode becomes severe. Technology adoption — particularly continuous glucose monitoring (CGM) systems that alert to declining glucose — can meaningfully address hypoglycemia risk and, when documented, provides underwriters with evidence that the risk is being actively managed through monitoring infrastructure rather than relying solely on symptom awareness.

Insulin Management Methods and Technology

The method by which a type 1 diabetes applicant manages insulin delivery and glucose monitoring provides underwriters with meaningful signals about the applicant’s engagement with their condition management. While no insulin delivery method automatically produces a better underwriting outcome than another, certain patterns of technology adoption and management infrastructure correlate with better metabolic control and provide objective evidence of active, systematic diabetes management.

Continuous glucose monitoring (CGM) adoption — whether linked to an insulin pump as a closed-loop system or used independently alongside multiple daily injections — provides underwriters with evidence that the applicant receives real-time glucose data throughout the day and has the technological infrastructure to detect and respond to glucose excursions before they become severe. CGM documentation, including time-in-range statistics if available from CGM download reports, provides a much more detailed picture of glucose control than A1C alone. Time-in-range data showing the percentage of readings within target glucose range supplements the A1C as a metabolic control indicator and can strengthen the underwriting narrative when time-in-range is favorable even if A1C is slightly elevated.

Insulin pump therapy, particularly closed-loop systems that automatically adjust insulin delivery based on real-time CGM readings, demonstrates sophisticated diabetes management infrastructure. Consistent pump usage with documented follow-up settings reviews and endocrinologist oversight presents as active, technology-supported management rather than static injection regimens. Neither pump therapy nor CGM use is required for favorable underwriting — many individuals with excellent control use multiple daily injections effectively — but their presence in the application documentation strengthens the narrative of engaged, evidence-supported management.

How Type 1 Differs From Type 2 in Underwriting — Why It Matters

Life insurance for type 1 diabetes and life insurance for type 2 diabetes involve the same general underwriting framework — A1C, complications, cardiovascular health — but they reflect meaningfully different actuarial risk profiles that carriers evaluate with different guidelines. Type 1 diabetes involves absolute insulin deficiency from autoimmune pancreatic destruction, requires lifelong insulin therapy regardless of lifestyle factors, and typically presents at younger ages. Type 2 diabetes involves insulin resistance and relative insulin insufficiency, is strongly associated with obesity and metabolic syndrome, and typically presents at older ages — though juvenile Type 2 is increasingly common.

The earlier age of onset for most type 1 diabetes applicants means a longer exposure period to the metabolic effects of the condition — and therefore a longer window during which complications can develop. This is why underwriters evaluate type 1 cases with particular attention to the trajectory of management quality over time and the current complication status at the applicant’s age. A 35-year-old with a 25-year history of type 1 diabetes with no complications and excellent control is being evaluated differently from a 35-year-old who has had the condition for only 5 years — because the longer history with clean complications documentation demonstrates sustained management quality in a way that a shorter history cannot. Our resource on life insurance for type 2 diabetes covers the Type 2 underwriting landscape, which provides useful contrast for understanding how carriers differentiate between the two conditions. Our resource on life insurance for kids with diabetes covers the pediatric context for both type 1 and type 2 presentations.

Product Options for Type 1 Diabetes Applicants

Once the underwriting profile for a type 1 diabetes applicant has been assessed and the appropriate carrier identified, the product selection decision follows the same framework as any other life insurance application — shaped by the coverage need, the timeline, the budget, and the extent to which permanent policy features such as cash value and conversion rights are priorities.

Term life insurance is typically the most cost-effective product for applicants whose primary goal is income replacement, mortgage protection, or family financial security during the years of maximum obligation. Fixed premiums for a defined term — 10, 15, 20, or 30 years — provide predictable budget management and maximum death benefit per premium dollar. Many term policies available to type 1 diabetes applicants include conversion provisions that allow the policy to be exchanged for a permanent policy without new underwriting at the original health class — a particularly valuable feature for type 1 applicants who anticipate that their health profile may become more complex over time. Permanent life insurance — whole life, guaranteed universal life, or indexed universal life — provides lifetime coverage and in most cases builds cash value. For type 1 applicants who qualify and whose planning objectives include lifetime coverage or long-range cash accumulation, permanent policies are evaluated on the same terms as for any other applicant at the assigned health class. Our resource on life insurance for overweight applicants covers how build ratings interact with diabetic underwriting when both variables are present in an application.

Interim Coverage When the Timing Is Not Right

Some type 1 diabetes applicants are in a period — recent DKA, elevated A1C in the process of improvement, recently begun new management technology — where the best outcome from a full underwriting application is not yet available. For these applicants, interim coverage while the management profile improves may be the most practical approach. Our resource on guaranteed issue burial insurance covers the no-underwriting option that can provide interim final expense protection during a waiting period, with the plan to transition to fully underwritten coverage when the clinical picture supports a more favorable application. Our resource on best independent life insurance broker covers the brokerage criteria that determine which advisor can most effectively navigate the complex carrier selection and application timing decisions involved in type 1 diabetes underwriting.